TSCAN THERAPEUTICS, INC. (TCRX) Operating cash flow 2020–2025
TSCAN THERAPEUTICS, INC. (TCRX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$135.3MFY2025 · since FY2020: -$3.0M → -$135.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$135.3M | -22.1% |
| FY2024 | -$110.8M | -80.6% |
| FY2023 | -$61.4M | +7.7% |
| FY2022 | -$66.5M | -36.6% |
| FY2021 | -$48.7M | -1510.2% |
| FY2020 | -$3.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TCRX financial trends
TCRX RevenueTCRX Net incomeTCRX Net marginTCRX Gross profitTCRX Gross marginTCRX Operating incomeTCRX Operating marginTCRX Free cash flowTCRX Capital expendituresTCRX Return on equityTCRX Stock buybacksTCRX Dividends paidTCRX Total assetsTCRX Total liabilitiesTCRX Shareholders’ equityTCRX overview →